Want to join the conversation?
Pharma company $MRK said a Phase 2 study of its investigational beta-lactamase inhibitor, relebactam, in combination with imipenem/cilastatin in patients with urinary tract infections met its primary endpoint. Two Phase 3 clinical studies of relebactam in combination with imipenem/cilastatin are currently ongoing and recruiting patients.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)